TScan Therapeutics Ownership | Who Owns TScan Therapeutics?

Overview Forecast RevenueFinancials Chart

TScan Therapeutics Ownership Summary

TScan Therapeutics is owned by 35.24% institutional investors, 0.82% insiders, and 63.93% retail investors. Lynx1 capital management lp is the largest institutional shareholder, holding 5.51% of TCRX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.57% of its assets in TScan Therapeutics shares.

TCRX Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	TScan Therapeutics	35.24%	0.82%	63.93%
Sector	Healthcare Stocks	49.73%	8.84%	41.43%
Industry	Biotech Stocks	47.04%	8.74%	44.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Lynx1 capital management lp	5.22M	5.51%	$30.56M
Ecor1 capital	5.00M	5.27%	$29.25M
Blackrock	4.46M	4.70%	$26.10M
Adage capital partners gp	4.40M	4.64%	$25.74M
Bvf inc/il	2.99M	3.15%	$17.49M
Baker bros. advisors lp	2.78M	2.94%	$16.29M
Vanguard group	2.13M	2.25%	$12.48M
Propel bio management	2.09M	2.20%	$12.21M
Deer management	1.25M	1.31%	$7.29M
Alphabet	1.08M	1.14%	$6.30M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Dc funds, lp	630.00K	61.20%	$3.69M
Propel bio management	2.09M	7.92%	$12.21M
Lynx1 capital management lp	5.22M	1.98%	$30.56M
Deer management	1.25M	1.50%	$7.29M
Stempoint capital lp	845.07K	1.45%	$4.94M
Great point partners	940.83K	1.05%	$5.50M
Ecor1 capital	5.00M	0.89%	$29.25M
Bvf inc/il	2.99M	0.49%	$17.49M
Simplify asset management	1.05M	0.41%	$6.12M
Alphabet	1.08M	0.32%	$6.30M

Top Buyers

Holder	Shares	% Assets	Change
Blackrock	4.46M	0.00%	2.76M
Great point partners	940.83K	1.05%	940.83K
Stempoint capital lp	845.07K	1.45%	845.07K
Lmr partners llp	665.53K	0.03%	665.53K
Adage capital partners gp	4.40M	0.05%	500.00K

Top Sellers

Holder	Shares	% Assets	Change
Millennium management	27.89K	0.00%	-364.23K
Paradigm biocapital advisors lp	-	-	-353.89K
Susquehanna group, llp	-	-	-297.90K
Goldman sachs group	35.27K	-	-224.88K
Alpine global management	-	-	-137.49K

New Positions

Holder	Shares	% Assets	Change	Value
Great point partners	940.83K	1.05%	940.83K	$5.50M
Stempoint capital lp	845.07K	1.45%	845.07K	$4.94M
Lmr partners llp	665.53K	0.03%	665.53K	$3.89M
Woodline partners lp	163.49K	0.01%	163.49K	$956.43K
Troluce capital advisors	92.83K	0.05%	92.83K	$543.07K

Sold Out

Holder	Change
Federated hermes	-56.00
Macquarie group	-1.62K
Lazard asset management	-2.55K
Cambridge investment research advisors	-10.06K
Jump financial	-10.79K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2024	86	10.26%	41,835,445	0.96%	35	1.85%	45	-8.16%	16	23.08%
Jun 30, 2024	78	18.18%	41,438,662	20.84%	43	1.60%	49	25.64%	13	44.44%
Mar 31, 2024	66	22.22%	34,293,057	7.46%	52	4.62%	39	14.71%	9	80.00%
Dec 31, 2023	54	68.75%	31,912,889	11.63%	33	0.92%	34	112.50%	5	400.00%
Sep 30, 2023	32	10.34%	28,588,231	2.22%	60	0.45%	16	14.29%	1	-75.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	1.37M	2.57%	-
BlackRock Health Sciences Term Trust	1.05M	1.97%	-
Simplify Propel Opportunities ETF	1.05M	1.96%	-
iShares Russell 2000 ETF	967.48K	1.83%	-2.17K
BlackRock Health Sciences Opps Inv A	681.01K	1.28%	-
Vanguard Institutional Extnd Mkt Idx Tr	641.74K	1.20%	-3.54K
Invesco Dorsey Wright SmallCap Momt ETF	475.53K	0.90%	-
Fidelity Small Cap Index	393.21K	0.74%	-12.58K
Fidelity Extended Market Index	283.47K	0.54%	16.74K
abrdn Life Sciences Investors	233.60K	0.44%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Dec 13, 2024	Lynx1 Capital Management LP	-	Buy	$290.14K
Dec 12, 2024	Lynx1 Capital Management LP	-	Buy	$95.63K
Nov 15, 2024	Lynx1 Capital Management LP	-	Buy	$4.11K
Sep 23, 2024	Klencke Barbara	-	Buy	$26.45K
Aug 23, 2024	Klencke Barbara	-	Buy	$28.45K

Insider Transactions Trends

Date	Buy	Sell
2024 Q3	3	1
2024 Q2	3	-
2024 Q1	-	-
2023 Q4	3	-
2023 Q3	-	-

TCRX Ownership FAQ

Who Owns TScan Therapeutics?

TScan Therapeutics shareholders are primarily institutional investors at 35.24%, followed by 0.82% insiders and 63.94% retail investors. The average institutional ownership in TScan Therapeutics's industry, Biotech Stocks , is 47.04%, which TScan Therapeutics falls below.

Who owns the most shares of TScan Therapeutics?

TScan Therapeutics’s largest shareholders are Lynx1 capital management lp (5.22M shares, 5.51%), Ecor1 capital (5M shares, 5.27%), and Blackrock (4.46M shares, 4.70%). Together, they hold 15.48% of TScan Therapeutics’s total shares outstanding.

Does Blackrock own TScan Therapeutics?

Yes, BlackRock owns 4.70% of TScan Therapeutics, totaling 4.46M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 26.1M$. In the last quarter, BlackRock increased its holdings by 2.76M shares, a 162.61% change.

Who is TScan Therapeutics’s biggest shareholder by percentage of total assets invested?

Dc funds, lp is TScan Therapeutics’s biggest shareholder by percentage of total assets invested, with 61.20% of its assets in 630K TScan Therapeutics shares, valued at 3.69M$.

Who is the top mutual fund holder of TScan Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of TScan Therapeutics shares, with 2.57% of its total shares outstanding invested in 1.37M TScan Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools